Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201

Ninomiya, Kiichiro; Hotta, Katsuyuki; Hisamoto-Sato, Akiko; Ichihara, Eiki; Gotoda, Hiroko; Morichika, Daisuke; Tamura, Tomoki; Kayatani, Hiroe; Minami, Daisuke; Kubo, Toshio; Tabata, Masahiro; Tanimoto, Mitsune; Kiura, Katsuyuki

doi:10.1007/s10147-015-0860-1

Cited by 25 publications

(20 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ninomiya et al conducted a prospective, low‐volume hydration feasibility trial (950 mL total during outpatient infusion and 3.5 L oral posthydration) in chemo‐naïve lung cancer patients ( n = 45) receiving cisplatin ≥60 mg/m 2 . During the first cycle, only one patient experienced grade ≥2 nephrotoxicity (2%), and five patients (11%) experienced a grade ≥1 event . Bohm et al also showed that low‐volume hydration (2.25 L total) provided nephroprotection in ovarian cancer patients ( n = 26) receiving cisplatin 90 mg/m 2 .…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity

et al. 2017

View full text Add to dashboard Cite

Hydration is essential for all patients to prevent cisplatin-induced nephrotoxicity. Specifically, short-duration, low-volume, outpatient hydration with magnesium supplementation and mannitol forced diuresis (in select patients) represent best practice principles for the safe use of cisplatin. 2017;22:609-619 IMPLICATIONS FOR PRACTICE: The findings contained within this systematic review show that (a) hydration is essential for all patients to prevent cisplatin-induced nephrotoxicity, (b) short-duration, low-volume, outpatient hydration regimens appear to be safe and feasible, even in patients receiving intermediate- to high-dose cisplatin, (c) magnesium supplementation (8-16 milliequivalents) may limit cisplatin-induced nephrotoxicity, and (d) mannitol may be considered for high-dose cisplatin and/or patients with preexisting hypertension. These findings have broad implications for clinical practice and represent best practice principles for the prevention of cisplatin-induced nephrotoxicity.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Early studies established the importance of CH during cisplatin administration in the inpatient setting. However, safe and effective cisplatin administration with short‐duration and/or low‐volume hydration is feasible in the outpatient setting .…”

Section: Discussionmentioning

confidence: 99%

A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The aprepitant regimen not only had a positive impact on health outcomes and QOL for patients receiving cisplatin-based chemotherapy, but also counterbalanced incremental total medical costs including indirect costs that would be wasted by CINV without it. 29 However, the ICER slightly exceeded the WTP threshold in the ICS (6 195 [30][31][32] Furthermore, aprepitant was used in an antiemetic regimen to prevent CINV in those studies. NK 1 RA and other newer generation antiemetics have markedly improved gastrointestinal toxicity induced by cisplatin, [12][13][14][15][33][34][35] which may enable oral hydration.…”

Section: Discussionmentioning

confidence: 98%

“…Univariate sensitivity analysis indicated that factors that mainly affected these results included cost of aprepitant and CR rate. Recently, short hydration was shown to improve QOL for patients who received cisplatin‐based chemotherapy . Furthermore, aprepitant was used in an antiemetic regimen to prevent CINV in those studies.…”

Section: Discussionmentioning

confidence: 99%

Cost‐effectiveness of aprepitant in Japanese patients treated with cisplatin‐containing highly emetogenic chemotherapy

et al. 2018

View full text Add to dashboard Cite

Chemotherapy‐induced nausea and vomiting (CINV) remains a major adverse event in cancer chemotherapy. Although aprepitant is effective in preventing CINV, an increment in financial burden for uniform use of aprepitant is a concern. The aim of the present study was to define the cost‐effectiveness of aprepitant from the perspective of the Japanese National Health Insurance system. Based on the results of a randomized phase II trial comparing an aprepitant‐containing regimen versus a nonaprepitant regimen in Japanese patients who received cisplatin‐containing highly emetogenic chemotherapy, a decision analytic model was developed. The incremental cost‐effectiveness ratio (ICER) was calculated both in the outpatient care setting (OCS) and in the inpatient care setting (ICS). The use of the aprepitant‐containing regimen was associated with improved quality of life compared with the nonaprepitant regimen, with an increment in quality‐adjusted life years (QALY) of 0.0016. The incremental total medical costs associated with the use of the aprepitant regimen were lower in the OCS than in the ICS, 6192 JPY (56.92 USD) and 9820 JPY (90.27 USD), respectively. The ICER was calculated as 3 906 698 JPY (35 910 USD) per QALY gained in the OCS and 6 195 781 JPY (56 952 USD) per QALY gained in the ICS. Cost‐effectiveness of the aprepitant‐containing antiemetic therapy was limited to the OCS, considering the threshold of willingness‐to‐pay commonly accepted (5 million JPY [45 960 USD] in Japan and 50 000 USD in the USA). The efficacy of aprepitant offsets the costs for revisiting clinics or rehospitalization added with rescue medications in the OCS.

show abstract

“…Single arm retrospective studies performed by Brock and Alberts (30), Tiseo et al (19) and Lavole et al (21) with patient numbers of 147, 107 and 357 showed the feasibility of short hydration for cisplatin administration. Four single arm prospective studies, one involving 44 patients and performed by Horinouchi et al (22), one involving 46 patients and performed by Hotta et al (23), one involving 45 patients and performed by Ninomiya et al (24) and one involving 46 patients and performed by Horinouchi et al (26) also demonstrated the safety of short hydration for cisplatin. In addition, Ouchi et al (27) retrospectively compared a short hydration protocol performed in 13 patients with a conventional hydration protocol performed in 17 patients and showed a similar safety between the two groups.…”

Section: Discussionmentioning

confidence: 99%

Safety of a short hydration method for cisplatin administration in comparison with a conventional method—a retrospective study

Sakaida

Iwasawa

Kurimoto

et al. 2016

Jpn. J. Clin. Oncol.

View full text Add to dashboard Cite

Objective: Cisplatin is administered in combination with massive hydration to avoid renal toxicity, making its administration difficult in an outpatient setting. Although a short hydration protocol for cisplatin has been recently developed, its safety is not fully understood. Methods: Consecutive patients with lung or other cancer and an Eastern Cooperative Oncology Group performance status of 0-2 who were receiving chemotherapy containing cisplatin at a dose of ≥60 mg/m 2 in a single administration were evaluated. Seventy-four patients were treated with a short hydration protocol consisting of 1750-2250 ml of hydration with mannitol and magnesium supplementation over a period of 3.75-4.75 h on Day 1. Sixty-nine patients were treated with a conventional hydration protocol consisting of 2100-2600 ml of hydration over 6.5-7.5 h on Day 1 with pre-and post-hydration on Days 0, 2 and 3. Toxicity was then compared between the two groups.Results: An elevated serum creatinine level ≥grade 1 was significantly less frequent in the group receiving the short hydration protocol than in the group receiving conventional hydration. Other toxicities were similar between the two groups. Consequently, the completion rate for the planned treatment in the short hydration group (73.0%, 54/74) was significantly higher than that in the conventional hydration group (53.6%, 37/69). Conclusions: Short hydration is safe, making cisplatin-containing chemotherapy easier to perform.

show abstract

Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201

Abstract: This prospective study demonstrated the safety and efficacy of shorter-term lower-volume hydration.

Cited by 25 publications

References 13 publications

A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity

A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity

Cost‐effectiveness of aprepitant in Japanese patients treated with cisplatin‐containing highly emetogenic chemotherapy

Safety of a short hydration method for cisplatin administration in comparison with a conventional method—a retrospective study

Contact Info

Product

Resources

About